Protozoal Intestinal Infections and Trichomoniasis¶
Chapter 236 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Giardia duodenalis is the most common intestinal protozoal parasite, causing global endemic and epidemic diarrhea, especially in children in resource-limited areas.
- Diagnosis requires detection of Giardia antigens, cysts, or trophozoites via stool exams, NAATs, or duodenal fluid analysis; metronidazole (500–750 mg TID x5 days) is first-line treatment.
- Cryptosporidium spp. (C. hominis, C. parvum) cause severe diarrhea in immunocompromised patients; nitazoxanide (500 mg BID x3 days) is FDA-approved for treatment.
- Trichomoniasis (T. vaginalis) is a major cause of symptomatic vaginitis; metronidazole (2 g single dose) is first-line therapy with concurrent partner treatment.
- Microsporidia (Enterocytozoon bieneusi, Encephalitozoon spp.) cause chronic diarrhea in AIDS patients; TMP-SMX is primary treatment with long-term suppressive therapy.
1. DEFINITION & OVERVIEW¶
Protozoal intestinal infections and trichomoniasis are caused by various parasites affecting the gastrointestinal tract and genitourinary system. Giardia duodenalis, Cryptosporidium spp., Cystoisospora belli, Cyclospora cayetanensis, Microsporidia, and Trichomonas vaginalis are key pathogens. These infections range from asymptomatic carriage to severe diarrhea and malabsorption, with significant morbidity in immunocompromised hosts.
Table 236-1 Diagnosis of Intestinal Protozoal Infections¶
| PARASITE | STOOL O+P | FECAL ACID-FAST STAIN | FECAL ANTIGEN IMMU NOASSAYS | FECAL NAATS | OTHER |
|---|---|---|---|---|---|
| Giardia | + | + | + | + | DFA |
| Cryptosporidium | ± | + | + | + | DFA |
| Cystoisospora | ± | + | + | + | |
| Cyclospora | ± | + | + | + | |
| Dientamoeba | ± | + | + | + | |
| Balantidium | + | + | + | + | |
| Microsporidia | – | + | + | + | Special fecal stains, tissue biopsies |
1.1 Protozoal Infections¶
Giardia, Cryptosporidium, Cystoisospora, Cyclospora, Microsporidia, and Trichomonas are major causative agents. Giardia and Cryptosporidium are waterborne pathogens, while Trichomonas is sexually transmitted. Microsporidia are opportunistic pathogens in immunocompromised patients.
1.2 Trichomoniasis¶
Trichomonas vaginalis is a flagellated protozoan causing genitourinary infections, primarily affecting the vagina in women and urethra in men. It is associated with increased risk of HIV transmission and other sexually transmitted infections.
2. EPIDEMIOLOGY¶
Giardia is the most common intestinal protozoal infection globally, with prevalence up to 40% in children in resource-limited areas. Cryptosporidium is second most common cause of moderate-to-severe diarrhea in children under 2 years. Trichomoniasis affects 2–3 million annually in the U.S., with highest prevalence among individuals with multiple sexual partners. Microsporidia are common in AIDS patients (10–40% of chronic diarrhea cases).
2.1 Risk Factors¶
Poor sanitation, contaminated water, close contact in daycare, immunocompromise, and sexual activity are key risk factors. Travel to endemic regions increases risk of Cyclospora and Cryptosporidium infections.
2.2 Demographics¶
Giardia and Cryptosporidium are most common in children, while Trichomoniasis is prevalent in sexually active adults. Microsporidia predominantly affect AIDS patients.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Giardia and Cryptosporidium are waterborne, while Trichomonas is sexually transmitted. Giardia causes malabsorption via epithelial damage; Cryptosporidium induces secretory diarrhea. Microsporidia disrupt intestinal epithelial function. Trichomonas causes inflammation and mucosal damage in the genitourinary tract.
3.1 Life Cycle¶
Giardia: Cysts → excystation → trophozoites → encystation. Cryptosporidium: Oocysts → sporozoites → replication. Trichomonas: Trophozoites → cysts (not formed). Microsporidia: Spores → intracellular multiplication.
3.2 Pathogenesis¶
Giardia: Apoptosis of enterocytes, epithelial barrier dysfunction. Cryptosporidium: Secretory diarrhea via cAMP activation. Trichomonas: Mucosal inflammation and immune response. Microsporidia: Intracellular proliferation causing epithelial damage.
4. CLINICAL FEATURES¶
Giardia: Asymptomatic (50%), acute diarrhea (1–3 weeks), chronic malabsorption. Cryptosporidium: Watery diarrhea, weight loss, dehydration. Trichomoniasis: Vaginal discharge, urethritis, dysuria. Microsporidia: Chronic diarrhea, weight loss, biliary tract involvement.
4.1 Symptoms¶
Giardia: Diarrhea, bloating, flatus, nausea. Cryptosporidium: Watery diarrhea, dehydration. Trichomoniasis: Vaginal discharge, urethritis, dysuria. Microsporidia: Chronic diarrhea, weight loss.
4.2 Complications¶
Malabsorption, lactose intolerance, growth retardation, biliary obstruction, and opportunistic infections in immunocompromised hosts.
5. DIFFERENTIAL DIAGNOSIS¶
Giardia vs. other intestinal parasites (Cryptosporidium, Cyclospora, Cystoisospora). Trichomoniasis vs. bacterial vaginosis, yeast infections, and other STIs. Microsporidia vs. other causes of chronic diarrhea (e.g., HIV enteropathy).
5.1 Key Differentiators¶
Giardia: Presence of cysts/trophozoites in stool. Cryptosporidium: Oocysts in stool. Trichomoniasis: Motile trichomonads in genital secretions. Microsporidia: Intracellular spores in biopsy.
6. INVESTIGATIONS & DIAGNOSIS¶
Stool exams (O+P, acid-fast stains), antigen detection, NAATs, and biopsy for microsporidia. Trichomoniasis diagnosed by wet mount or NAATs. Cryptosporidium requires specialized staining (DFA) or NAATs.
6.1 Diagnostic Tests¶
Stool O+P, fecal antigen assays, NAATs, modified acid-fast stains, and duodenal fluid analysis. Biopsy for microsporidia and Cryptosporidium.
6.2 Algorithms¶
Diagnosis of Giardia: Stool antigen/NAAT. Cryptosporidium: Stool O+P + DFA/NAAT. Trichomoniasis: Wet mount or NAAT. Microsporidia: Biopsy + NAAT.
7. MANAGEMENT & TREATMENT¶
Giardia: Metronidazole (500–750 mg TID x5 days), tinidazole (2 g single dose), or nitazoxanide (500 mg BID x3 days). Cryptosporidium: Nitazoxanide (FDA-approved), TMP-SMX for HIV patients. Trichomoniasis: Metronidazole (2 g single dose) or tinidazole (2 g single dose). Microsporidia: TMP-SMX with long-term suppressive therapy.
7.1 Pharmacologic Therapy¶
Giardia: Metronidazole (500–750 mg TID x5 days), tinidazole (2 g single dose), nitazoxanide (500 mg BID x3 days). Cryptosporidium: Nitazoxanide, TMP-SMX. Trichomoniasis: Metronidazole (2 g single dose), tinidazole (2 g single dose). Microsporidia: TMP-SMX (160/800 mg TID x7–10 days).
7.2 Non-Pharmacologic¶
Hydration, electrolyte replacement, and prevention of reinfection (e.g., water filtration, safe sex practices).
8. PROGNOSIS & COMPLICATIONS¶
Most patients recover with treatment, but chronic infections may persist. Complications include malabsorption, dehydration, and opportunistic infections in immunocompromised hosts. Untreated infections can lead to long-term sequelae like lactose intolerance and growth retardation.
8.1 Prognosis¶
Giardia: >90% cure rate with metronidazole. Cryptosporidium: Improved with immune reconstitution. Trichomoniasis: High cure rate with metronidazole. Microsporidia: Requires long-term suppressive therapy.
8.2 Complications¶
Malabsorption, lactose intolerance, biliary obstruction, and increased risk of HIV transmission in trichomoniasis.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid metronidazole; use paromomycin or nitazoxanide. Pediatrics: Giardia and Cryptosporidium are common; monitor for dehydration. Elderly: Risk of dehydration and drug interactions. Immunocompromised: Require prolonged therapy and prophylaxis.
9.1 Pregnancy¶
Avoid metronidazole; use paromomycin or nitazoxanide for Giardia. Trichomoniasis: Metronidazole may be used in late pregnancy.
9.2 Immunocompromised¶
Microsporidia and Cryptosporidium require long-term suppressive therapy. Trichomoniasis increases HIV transmission risk.
10. KEY POINTS & CLINICAL PEARLS¶
- Giardia is the most common intestinal protozoal infection; treat with metronidazole or nitazoxanide. 2. Cryptosporidium is severe in immunocompromised patients; use nitazoxanide. 3. Trichomoniasis is a major STI; treat all partners with metronidazole. 4. Microsporidia require long-term TMP-SMX therapy. 5. Prevention includes safe water, hygiene, and safe sex practices.